Patents by Inventor Michael Cannarile

Michael Cannarile has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL BIOMARKERS AND USES THEREOF
    Publication number: 20240094212
    Abstract: Disclosed herein are novel biomarkers for identifying patients, with cancer, likely to benefit from treatment with an anti-CD25 agent. Also disclosed are methods using said biomarkers for making a treatment decision—or monitoring treatment with an anti-CD25 agent as well as methods of treating a patient, with cancer, comprising administering an anti-CD25 agent based on prior use of the present biomarkers.
    Type: Application
    Filed: August 31, 2023
    Publication date: March 21, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael CANNARILE, Bruno GOMES, Vaios KARANIKAS, Theresa KOLBEN, Dominik RUETTINGER, Fabian SCHMICH
  • Dosages
    Publication number: 20230340110
    Abstract: The present invention relates to a treatment regime, including an antibody or antigen-binding fragment which is capable of binding specifically to colony stimulating factor-1 receptor (CSF-1R) for use in the treatment of tenosynovial giant cell tumour (TGCT) in a subject, as well as associated uses and methods.
    Type: Application
    Filed: November 1, 2022
    Publication date: October 26, 2023
    Applicant: Synox Therapeutics UK Limited
    Inventors: Axel Mescheder, Raymond Barlow, Michael Cannarile, Georgina Meneses-Lorente
  • Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment
    Patent number: 11498968
    Abstract: The current invention relates to the combination therapy of an anti-CSF-1R antibody (especially a CSF-1R dimerization inhibitor) in combination with an anti-PD-L1 antibody after PD1/PD-L1 inhibitor treatment failure, corresponding pharmaceutical compositions or medicaments using such combination therapy.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: November 15, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Cannarile, Anna-Maria Jegg, Francesca Michielin, Carola Ries, Dominik Ruettinger, Martin Weisser
  • Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment
    Publication number: 20190309078
    Abstract: The current invention relates to the combination therapy of an anti-CSF-1R antibody (especially a CSF-1R dimerization inhibitor) in combination with an anti-PD-L1 antibody after PD1/PD-L1 inhibitor treatment failure, corresponding pharmaceutical compositions or medicaments using such combination therapy.
    Type: Application
    Filed: June 11, 2019
    Publication date: October 10, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Michael CANNARILE, Anna-Maria JEGG, Francesca MICHIELIN, Carola RIES, Dominik RUETTINGER, Martin WEISSER
  • COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20190185572
    Abstract: The present invention relates to the combination therapy of antibodies binding to human CSF-1R, characterized in binding to the (dimerization) domains D4 to D5 (SEQ ID No: 85) of the extracellular domain of human CSF-1R in combination with a chemotherapeutic agent, radiation, and/or cancer immunotherapy.
    Type: Application
    Filed: December 4, 2018
    Publication date: June 20, 2019
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Michael CANNARILE, Carola RIES, Dominik RUETTINGER, Katharina WARTHA
  • COMBINATION THERAPY OF ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF
    Publication number: 20170247459
    Abstract: The present invention relates to the combination therapy of antibodies binding to human CSF-1R, characterized in binding to the (dimerization) domains D4 to D5 (SEQ ID No: 85) of the extracellular domain of human CSF-1R in combination with a chemotherapeutic agent, radiation, and/or cancer immunotherapy.
    Type: Application
    Filed: October 7, 2016
    Publication date: August 31, 2017
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Michael CANNARILE, Carola RIES, Dominik RUETTINGER, Katharina WARTHA
  • MARKERS FOR THE RESPONSIVENESS TO ANTI-CD44 ANTIBODIES
    Publication number: 20150044232
    Abstract: The present invention relates to means and methods of determining whether a tumor cell or a cancer cell is responsive to an anti-CD44 antibody or to an antigen binding fragment thereof. The method comprises the determination of the major CD44 isoform in a sample, wherein if the major CD44 isoform is CD44s, the tumor cell or cancer cell is responsive to said anti-CD44 antibody. Also means and methods of treating a cancer patient that has been determined to respond to an anti-CD44 antibody are subject of the present invention.
    Type: Application
    Filed: June 12, 2014
    Publication date: February 12, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Fabian Birzele, Michael Cannarile, Friedrich Feuerhake, Thomas Fischer, Florian Heil, Konrad Honold, Adam Nopora, Annette Schmitt-Graeff, Edgar Voss, Stefan Weigand